Coherus Biosciences | CHRS - Current Assets


Coherus Biosciences reported $206.71M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 649.88M 21.55M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Baxter International USD 6.87B 61M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Fujifilm JPY 1.72T 120.76B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Myriad Genetics USD 332.6M 12.2M Dec/2025
Pacira USD 547.97M 14.78M Dec/2025
Perrigo USD 2.8B 81.8M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Teva Pharmaceutical Industries USD 13.95B 1.21B Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xencor USD 599.82M 81.38M Dec/2025
Zoetis USD 6.77B 185M Dec/2025